Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31384427 | 1.00 | ROCK2 (0.52) | ROCK2HPGD | |
| SCHEMBL17924596 | 0.83 | ROCK2 (0.44) | ROCK2 | |
| SCHEMBL17930294 | 0.83 | ROCK2 (0.48) | ROCK2 | |
| SCHEMBL31152065 | 0.83 | ROCK2 (0.48) | ROCK2 | |
| SCHEMBL17930321 | 0.80 | ROCK2 (0.42) | ROCK2 | |
| SCHEMBL28304715 | 0.80 | ROCK2 (0.46) | ROCK2 | |
| SCHEMBL17924630 | 0.80 | ROCK2 (0.43) | ROCK2HPGD | |
| SCHEMBL30733666 | 0.79 | ROCK2 (0.46) | ROCK2 | |
| SCHEMBL2274451 | 0.79 | ROCK2 (0.46) | ROCK2 | |
| SCHEMBL20262375 | 0.79 | ROCK2 (0.45) | ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 288 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112945912-B | High-brightness large-Stokes-shift wash-free lipid-droplet fluorescent probe and synthetic method and application thereof | 中国科学院大连化学物理研究所 | 2023-02-21 | — | — | CN | claimed |
| US-20220274955-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS, INC. | 2022-09-01 | — | — | US | claimed |
| CN-112945912-A | High-brightness large-Stokes-shift wash-free lipid-droplet fluorescent probe and synthetic method and application thereof | 中国科学院大连化学物理研究所 | 2021-06-11 | — | — | CN | claimed |
| US-10053426-B2 | Process for the synthesis of metyrapone and alkylated metyrapone analogs | ALBEMARLE CORPORATION (US) | 2018-08-21 | — | — | US | claimed |
| US-20170334854-A1 | One-Step Process For The Synthesis Of Alkylated Metyrapone Analogs | W. R. GRACE & CO.-CONN. | 2017-11-23 | — | — | US | claimed |
| EP-3237383-A1 | ONE-STEP PROCESS FOR THE SYNTHESIS OF ALKYLATED METYRAPONE ANALOGS | Albemarle Corporation (US) | 2017-11-01 | — | — | EP | claimed |
| WO-2016105619-A1 | ONE-STEP PROCESS FOR THE SYNTHESIS OF ALKYLATED METYRAPONE ANALOGS | ALBEMARLE CORPORATION (US) | 2016-06-30 | — | — | WO | claimed |
| US-20260098026-A1 | M4 ACTIVATORS/MODULATORS AND USES THEREOF | CEREVEL THERAPEUTICS LLC (US) | 2026-04-09 | — | — | US | disclosed |
| US-12577258-B2 | Macrocyclic compound | VERNALIS (R&D) LIMITED (GB) | 2026-03-17 | — | — | US | disclosed |
| US-20260028331-A1 | Methods And Intermediates for Preparing 2-[(4-{6-[(4-Cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid, 1,3-Dihydroxy-2-(hydroxymethyl)propan-2-amine Salt | PFIZER INC. (US) | 2026-01-29 | — | — | US | disclosed |
| EP-3573972-B1 | RORGAMMA MODULATORS AND USES THEREOF | GENFIT (FR) | 2026-01-14 | — | — | EP | disclosed |
| EP-4649077-A1 | SPIRO DERIVATIVES AS M4 ACTIVATORS/MODULATORS AND USES THEREOF | Cerevel Therapeutics, LLC (US) | 2025-11-19 | — | — | EP | disclosed |
| US-20250320195-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS INC (US) | 2025-10-16 | — | — | US | disclosed |
| EP-2081916-A1 | OXADIAZOLE DERIVATIVES WITH ANTI-INFLAMMATORY AND IMMUNOSUPPRESSIVE PROPERTIES | Novartis AG (CH) | 2009-07-29 | — | — | EP | disclosed |
| US-20080306124-A1 | Polycyclic Oxadiazoles or I Soxazoles and Their Use as Sip Receptor Ligands | NOVARTIS AG (CH) | 2008-12-11 | — | — | US | disclosed |
| WO-2008037476-A1 | OXADIAZOLE DERIVATIVES WITH ANTI-INFLAMMATORY AND IMMUNOSUPPRESSIVE PROPERTIES | NOVARTIS AG (CH) | 2008-04-03 | — | — | WO | disclosed |
| EP-1893591-A1 | POLYCYCLIC OXADIAZOLES OR I SOXAZOLES AND THEIR USE AS SlP RECEPTOR LIGANDS | Novartis AG (CH) | 2008-03-05 | — | — | EP | disclosed |
| EP-1778639-A2 | ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | AMR Technology, Inc. (US) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006131336-A1 | POLYCYCLIC OXADIAZOLES OR I SOXAZOLES AND THEIR USE AS SlP RECEPTOR LIGANDS | NOVARTIS AG (CH) | 2006-12-14 | — | — | WO | disclosed |
| WO-2006020049-A2 | ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | AMR TECHNOLOGY, INC. (US) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577258-B2 | Macrocyclic compound | IRAK1, IRAK4, IRAK2 | ROCK2 3397/4885HPGD 4590/4885 |
| US-20260098026-A1 | M4 ACTIVATORS/MODULATORS AND USES THEREOF | CHRM1, CHRM2, CHRM4 | ROCK2 985/4885HPGD 3237/4885 |
| US-20170334854-A1 | One-Step Process For The Synthesis Of Alkylated Metyrapone Analogs | MET, MEP1B, ABL1 | ROCK2 2936/4885HPGD 1605/4885 |
| US-20260028331-A1 | Methods And Intermediates for Preparing 2-[(4-{6-[(4-Cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid, 1,3-Dihydroxy-2-(hydroxymethyl)propan-2-amine Salt | ADH1C, TET2, ADH1A | ROCK2 1043/4885HPGD 2375/4885 |
| US-20080306124-A1 | Polycyclic Oxadiazoles or I Soxazoles and Their Use as Sip Receptor Ligands | SOX18, SIGMAR1, SUCNR1 | ROCK2 2745/4885HPGD 2500/4885 |
| US-20220274955-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | MDM2, CRBN, VHL | ROCK2 3555/4885HPGD 1369/4885 |
| US-20250320195-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | MDM2, CRBN, VHL | ROCK2 3555/4885HPGD 1369/4885 |
| US-10053426-B2 | Process for the synthesis of metyrapone and alkylated metyrapone analogs | MET, ABL1, CMPK1 | ROCK2 2501/4885HPGD 1344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.